Last reviewed · How we verify

Pethidin

Ain Shams University · FDA-approved active Small molecule Quality 19/100

Pethidin, marketed by Ain Shams University, is a general anesthetic currently available in the market. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity that could help maintain its market position. However, the lack of reported revenue and key trial results poses a significant risk in assessing its competitive landscape and long-term viability.

At a glance

Generic namePethidin
Also known asMIDAZOLAM-PETHIDIN
SponsorAin Shams University
TargetSolute carrier family 22 member 1, Glutamate receptor ionotropic, NMDA 3A, Kappa-type opioid receptor
ModalitySmall molecule
Therapeutic areaPain
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: